Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye

To improve adherence to 0.01% atropine treatment for progressive myopia in our patient population, patient education and enhanced support systems are essential. Implementing strategies to address challenges related to monthly renewal and providing better information about the long-term benefits of treatment could help increase adherence rates.